Moxifloxacin Kabi (Moxifloxacin Hydrochloride)

Moxifloxacin hydrochloride exerts its antibacterial effect by inhibiting two essential bacterial enzymes, DNA gyrase (topoisomerase II) and topoisomerase IV. By binding to the enzyme‑DNA complex, it prevents DNA supercoiling and replication, halting transcription and leading to bacterial cell death. This dual inhibition provides activity against a wide range of Gram‑positive, Gram‑negative and atypical pathogens.

The specific dose and duration of Moxifloxacin Kabi are determined by the prescribing clinician based on the infection type, severity, patient weight, renal and hepatic function, and local antimicrobial guidelines. Healthcare professionals should follow the product label and institutional protocols when selecting the appropriate regimen.

The safety of Moxifloxacin Kabi in pregnancy and lactation has not been established. It is classified as a pregnancy category unknown, and use is generally reserved for situations where the potential benefit justifies any potential risk to the fetus or infant. Clinicians should discuss alternatives and risk‑benefit considerations with the patient.

To place an order, visit the product page on gnhindia.com, enter the required quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and necessary import documentation.

Compared with earlier fluoroquinolones such as ciprofloxacin or levofloxacin, moxifloxacin offers enhanced activity against Gram‑positive organisms and atypical pathogens, and a longer half‑life that allows once‑daily dosing in oral formulations. However, safety considerations such as QT prolongation and tendon toxicity remain class‑related, and selection should be guided by susceptibility data and patient risk factors.

Moxifloxacin Kabi should be stored at 2 °C to 8 °C (refrigerated). Keep the vials in the original packaging, protect them from light, and avoid freezing or shaking the solution. If temperature excursions occur, discard the product according to local regulations.

The product is supplied as a sterile injectable solution for intravenous infusion. It is typically diluted in an appropriate compatible IV fluid and administered over a prescribed period, usually 30–60 minutes, under aseptic conditions. Administration guidelines, including infusion rate and compatible diluents, are provided in the product labeling.

The most serious adverse reactions include tendon rupture, especially in older adults; QT interval prolongation that can precipitate ventricular arrhythmias; severe hypersensitivity reactions such as anaphylaxis; and Clostridioides difficile‑associated colitis. Patients should be monitored for musculoskeletal pain, cardiac symptoms, and signs of infection during therapy.

Moxifloxacin Kabi is contraindicated in patients with a known hypersensitivity to moxifloxacin, other fluoroquinolones, or any of the product excipients. Caution is advised, and it is generally avoided, in individuals with a history of tendon disorders, uncontrolled arrhythmias, or those receiving other QT‑prolonging agents. Clinical judgment should guide use in pregnant or lactating women.